Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INSM Insmed	$100.28 -1.3%	$72.79	$60.40 ▼ $102.00	$18.73B	0.8	2.16 million shs	2.59 million shs
REGN Regeneron Pharmaceuticals	$508.86 -2.6%	$561.15	$476.49 ▼ $1,211.20	$57.14B	0.31	879,394 shs	889,852 shs
TAK Takeda Pharmaceutical	$14.89 -1.2%	$14.74	$12.58 ▼ $15.68	$48.37B	0.23	1.95 million shs	2.23 million shs
ZTS Zoetis	$161.63 -1.7%	$159.23	$139.70 ▼ $200.33	$73.16B	0.94	2.54 million shs	2.20 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INSM Insmed	-1.29%	+10.28%	+47.21%	+27.03%	+54.99%
REGN Regeneron Pharmaceuticals	-2.64%	-2.80%	-14.38%	-24.32%	-51.32%
TAK Takeda Pharmaceutical	-1.16%	-2.39%	+5.57%	-1.62%	+13.06%
ZTS Zoetis	-1.66%	-3.27%	-0.86%	-1.30%	-5.41%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
INSM Insmed	3.3155 of 5 stars	2.5	1.0	0.0	4.3	2.7	1.7	0.6
REGN Regeneron Pharmaceuticals	4.8719 of 5 stars	4.4	4.0	1.7	2.3	3.3	1.7	1.9
TAK Takeda Pharmaceutical	1.9129 of 5 stars	0.0	3.0	1.7	0.0	1.8	0.0	2.5
ZTS Zoetis	4.5912 of 5 stars	3.6	3.0	4.2	0.4	3.1	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
INSM Insmed	3.00	Buy	$104.81	4.52% Upside
REGN Regeneron Pharmaceuticals	2.85	Moderate Buy	$836.48	64.38% Upside
TAK Takeda Pharmaceutical	3.00	Buy	N/A	N/A
ZTS Zoetis	3.10	Buy	$212.75	31.63% Upside

Current Analyst Ratings Breakdown

Latest INSM, ZTS, REGN, and TAK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	INSM Insmed	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$100.00 ➝ $112.00
6/11/2025	INSM Insmed	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$96.00 ➝ $110.00
6/11/2025	INSM Insmed	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$99.00 ➝ $106.00
6/11/2025	INSM Insmed	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$90.00 ➝ $102.00
6/11/2025	INSM Insmed	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$107.00 ➝ $119.00
6/11/2025	INSM Insmed	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$94.00 ➝ $109.00
6/11/2025	INSM Insmed	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$90.00 ➝ $120.00
6/10/2025	INSM Insmed	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/10/2025	INSM Insmed	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy
6/10/2025	INSM Insmed	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$100.00 ➝ $115.00
6/9/2025	REGN Regeneron Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$950.00 ➝ $800.00

(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
INSM Insmed	$363.71M	52.31	N/A	N/A	$1.60 per share	62.68
REGN Regeneron Pharmaceuticals	$14.20B	3.87	$43.94 per share	11.58	$268.50 per share	1.90
TAK Takeda Pharmaceutical	$30.09B	1.57	$3.12 per share	4.78	$14.39 per share	1.03
ZTS Zoetis	$9.26B	7.77	$6.95 per share	23.24	$10.57 per share	15.29

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
INSM Insmed	-$913.77M	-$5.95	N/A	N/A	N/A	-265.93%	-446.98%	-52.70%	8/6/2025 (Estimated)
REGN Regeneron Pharmaceuticals	$4.41B	$39.28	12.95	13.38	1.91	31.94%	15.27%	11.93%	7/30/2025 (Estimated)
TAK Takeda Pharmaceutical	$712.33M	$0.22	67.68	9.02	N/A	2.36%	10.64%	5.14%	7/30/2025 (Estimated)
ZTS Zoetis	$2.49B	$5.57	29.02	23.95	2.73	27.12%	55.48%	19.14%	8/5/2025 (Estimated)

Latest INSM, ZTS, REGN, and TAK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	INSM Insmed	-$1.36	-$1.42	-$0.06	-$1.42	$91.63 million	$92.82 million
5/8/2025	Q4 2025	TAK Takeda Pharmaceutical	$0.24	$0.16	-$0.08	-$0.21	$8.02 billion	$7.34 billion
5/6/2025	Q1 2025	ZTS Zoetis	$1.40	$1.48	+$0.08	$1.41	$2.20 billion	$2.22 billion
4/29/2025	Q1 2025	REGN Regeneron Pharmaceuticals	$8.83	$8.22	-$0.61	$7.27	$3.40 billion	$3.03 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
INSM Insmed	N/A	N/A	N/A	N/A	N/A
REGN Regeneron Pharmaceuticals	$3.52	0.69%	N/A	8.96%	N/A
TAK Takeda Pharmaceutical	$0.27	1.81%	N/A	122.73%	N/A
ZTS Zoetis	$2.00	1.24%	N/A	35.91%	14 Years

Latest INSM, ZTS, REGN, and TAK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/22/2025	ZTS Zoetis	quarterly	$0.50	1.2%	7/18/2025	7/18/2025	9/3/2025
5/20/2025	REGN Regeneron Pharmaceuticals	quarterly	$0.88	0.6%	5/20/2025	5/20/2025	6/6/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
INSM Insmed	2.03	6.37	5.99
REGN Regeneron Pharmaceuticals	0.09	4.73	3.95
TAK Takeda Pharmaceutical	0.63	1.31	0.72
ZTS Zoetis	1.09	1.75	1.08

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
INSM Insmed	N/A
REGN Regeneron Pharmaceuticals	83.31%
TAK Takeda Pharmaceutical	9.17%
ZTS Zoetis	92.80%

Insider Ownership

Company	Insider Ownership
INSM Insmed	3.00%
REGN Regeneron Pharmaceuticals	7.02%
TAK Takeda Pharmaceutical	0.04%
ZTS Zoetis	0.16%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
INSM Insmed	1,271	189.71 million	184.02 million	Optionable
REGN Regeneron Pharmaceuticals	15,106	107.96 million	100.39 million	Optionable
TAK Takeda Pharmaceutical	49,281	3.18 billion	3.18 billion	Optionable
ZTS Zoetis	13,800	445.21 million	444.50 million	Optionable

INSM, ZTS, REGN, and TAK Headlines

Recent News About These Companies

Janney Montgomery Scott LLC Purchases 4,196 Shares of Zoetis Inc. (NYSE:ZTS)

June 18 at 4:15 AM | marketbeat.com

Mission Wealth Management LP Boosts Holdings in Zoetis Inc. (NYSE:ZTS)

June 18 at 4:14 AM | marketbeat.com

William Blair Keeps Their Buy Rating on Zoetis (ZTS)

June 18 at 3:21 AM | theglobeandmail.com

Zoetis downgraded to Hold from Buy at Stifel

June 18 at 3:21 AM | msn.com

Zoetis Inc. (NYSE:ZTS) Shares Sold by Wendell David Associates Inc.

June 17 at 7:18 AM | marketbeat.com

PKO Investment Management Joint Stock Co Grows Holdings in Zoetis Inc. (NYSE:ZTS)

June 17 at 6:55 AM | marketbeat.com

Chicago Capital LLC Buys 5,097 Shares of Zoetis Inc. (NYSE:ZTS)

June 17 at 5:56 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Stock Position Decreased by Vista Investment Partners LLC

June 17 at 5:38 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Stake Boosted by Grove Bank & Trust

June 17 at 5:00 AM | marketbeat.com

QRG Capital Management Inc. Trims Stake in Zoetis Inc. (NYSE:ZTS)

June 17 at 4:44 AM | marketbeat.com

Dynamic Advisor Solutions LLC Acquires New Position in Zoetis Inc. (NYSE:ZTS)

June 17 at 3:50 AM | marketbeat.com

Here's Why Zoetis (ZTS) is a Strong Momentum Stock

June 16 at 10:50 AM | zacks.com

Zoetis Inc. (NYSE:ZTS) Shares Acquired by Precedent Wealth Partners LLC

June 16 at 7:25 AM | marketbeat.com

Great Lakes Retirement Inc. Takes $1.94 Million Position in Zoetis Inc. (NYSE:ZTS)

June 16 at 7:17 AM | marketbeat.com

Brown Miller Wealth Management LLC Makes New Investment in Zoetis Inc. (NYSE:ZTS)

June 16 at 6:30 AM | marketbeat.com

Bank Pictet & Cie Europe AG Reduces Stock Position in Zoetis Inc. (NYSE:ZTS)

June 16 at 5:31 AM | marketbeat.com

Mn Services Vermogensbeheer B.V. Sells 12,400 Shares of Zoetis Inc. (NYSE:ZTS)

June 15 at 9:02 AM | marketbeat.com

Vaughan Nelson Investment Management L.P. Has $200.06 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

June 14, 2025 | marketbeat.com

Raub Brock Capital Management LP Sells 3,028 Shares of Zoetis Inc. (NYSE:ZTS)

June 14, 2025 | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Bought by Campbell Newman Asset Management Inc.

June 14, 2025 | marketbeat.com

Tritonpoint Wealth LLC Sells 3,053 Shares of Zoetis Inc. (NYSE:ZTS)

June 14, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

INSM, ZTS, REGN, and TAK Company Descriptions

Insmed NASDAQ:INSM

$100.28 -1.31 (-1.29%)

Closing price 06/17/2025 04:00 PM Eastern

Extended Trading

$100.50 +0.22 (+0.22%)

As of 04:52 AM Eastern

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Regeneron Pharmaceuticals NASDAQ:REGN

$508.86 -13.82 (-2.64%)

Closing price 06/17/2025 04:00 PM Eastern

Extended Trading

$510.12 +1.26 (+0.25%)

As of 04:09 AM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Takeda Pharmaceutical NYSE:TAK

$14.89 -0.18 (-1.19%)

Closing price 06/17/2025 03:59 PM Eastern

Extended Trading

$15.68 +0.79 (+5.30%)

As of 04:00 AM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Zoetis NYSE:ZTS

$161.63 -2.75 (-1.67%)

Closing price 06/17/2025 03:59 PM Eastern

Extended Trading

$160.10 -1.54 (-0.95%)

As of 04:25 AM Eastern

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time